Description
InformationRBN-2397 RBN-2397 is a potent, selective and orally active NAD+ competitive inhibitor PARP7 with IC50 of <3 nM and Kd of <0.001 µM. RBN-2397 has the potential for the research of tumor treatment.TargetsPARP7 (Cell-free assay); PARP7 (Cell-free assay) <0.001 µM(Kd); <3 nMIn vitroRBN-2397 restores cytosolic nucleic acid sensing and blocks cell proliferation in a human lung cancer cell line.In vivoRBN-2397 causes complete regressions in human NSCLC NCI-H1373 xenografts and dose-dependent pharmacodynamic effects. RBN-2397 induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses.Cell Research(from reference)Cell lines：NCI-H1373 human lung cancer cells Concentrations：0.4 nM to 1000 nM Incubation Time：24 h